Autres langues Absci Corporation

Actions

ABSI

US00091E1091

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
4,58 ^USD	+2,81 %		-3,98 %	+9,05 %

21/03	Absci Corporation annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
21/03	Absci Corporation annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024	16/04
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024	16/04
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference	28/03
Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	21/03
Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Absci Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results	21/03
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	01/03
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	01/03
Absci Announces Pricing of Public Offering of Common Stock	28/02
Absci Announces Proposed Public Offering of Common Stock	27/02
Absci Announces Proposed Public Offering of Common Stock	27/02
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI	21/02
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI	21/02
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai	21/02
Absci to Participate in Upcoming Investor Conferences	20/02
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors	10/01
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors	10/01
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	08/01
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Absci Corporation

Actions

ABSI

US00091E1091

Autres langues

Filtres